Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Comment] Should aspirin and PPIs be recommended for patients with Barrett’s oesophagus?

During the past two decades, beneficial effects from aspirin, statins, and non-steroidal anti-inflammatory drugs (NSAIDS) have been observed in epidemiological studies, initially as preventive medicine for cardiovascular disease. Protective effects have also been seen against several cancer types, including malignancies of the gastrointestinal tract. This protection was first described for colorectal cancer and later also for oesophageal adenocarcinoma.1 The incidence of oesophageal adenocarcinoma has increased by ten times during the past 40 years.